Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion

Technology appraisal guidance
Reference number: TA283
Published: 22 May 2013
Last updated: 20 May 2024

Macular oedema (retinal vein occlusion) - ranibizumab: Novartis DSU comments

Macular oedema (retinal vein occlusion) - ranibizumab: Novartis DSU comments

Macular oedema (retinal vein occlusion) - ranibizumab: Novartis DSU comments
11 April 2013
(165.63 Kb 48 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 09 April 2013